Search
Thalys Medical has issued a statement regarding its associated company, Wuhan Huajinian Biotechnology Development Co., Ltd. (Huajinian Biotechnology), in which Thalys Medical holds a 15.61% equity stake, amounting to an investment of RMB 10.666 million made in January 2020. In 2024, Huajinian Biotechnology reported an operating revenue of RMB 26,800 and incurred a net loss of RMB 2.3823 million. Notably, the company's therapeutic antihypertensive vaccine project, HJY-ATRQ β-001, has successfully completed conceptual validation and preclinical research, with its Investigational New Drug (IND) application being approved by the National Medical Products Administration (NMPA) on June 6, 2025. Despite this progress, the project must still navigate Phase I and Phase II clinical trials, and there remain considerable uncertainties surrounding the ultimate success of these trials.
-
C114 Communication Network -
Communication Home
